{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=15",
    "query": {
      "intervention": "Vehicle solution",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 454,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T06:53:09.867Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03804268",
      "title": "Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "OTHER"
        },
        {
          "name": "Pilocarpine HCl Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 323,
      "start_date": "2018-12-21",
      "completion_date": "2019-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-28",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 36,
      "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Beverly Hills, California + 32 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03804268"
    },
    {
      "nct_id": "NCT04792580",
      "title": "The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Graft-versus-host-disease",
        "Ocular Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard W Yee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-10-22",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 1,
      "location_summary": "Bellaire, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04792580"
    },
    {
      "nct_id": "NCT04523142",
      "title": "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease (DED)"
      ],
      "interventions": [
        {
          "name": "CyclASol Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novaliq GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2021-01-04",
      "completion_date": "2022-05-23",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Newport Beach, California • Carmel, Indiana + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04523142"
    },
    {
      "nct_id": "NCT04734197",
      "title": "A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Betamethasone Sodium Phosphate 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine 0.05% Ophthalmic Emulsion",
          "type": "DRUG"
        },
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 349,
      "start_date": "2021-01-11",
      "completion_date": "2022-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Azusa, California • Hemet, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734197"
    },
    {
      "nct_id": "NCT05992922",
      "title": "A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "IC265 Ophthalmic Solution 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution (Vehicle)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iacta Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-10-17",
      "completion_date": "2023-12-19",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05992922"
    },
    {
      "nct_id": "NCT04983589",
      "title": "A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "Pilocarpine HCl",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 230,
      "start_date": "2021-09-02",
      "completion_date": "2022-02-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Glendale, California • Inglewood, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983589"
    },
    {
      "nct_id": "NCT02022215",
      "title": "Efficacy and Safety Study of ME1111 in Patients With Onychomycosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Onychomycosis"
      ],
      "interventions": [
        {
          "name": "ME1111 Solution, Low strength",
          "type": "DRUG"
        },
        {
          "name": "ME1111 Solution, High strength",
          "type": "DRUG"
        },
        {
          "name": "Matching Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Meiji Seika Pharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 304,
      "start_date": "2013-12-19",
      "completion_date": "2016-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Encinitas, California • San Diego, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02022215"
    },
    {
      "nct_id": "NCT07578363",
      "title": "An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hyperemia"
      ],
      "interventions": [
        {
          "name": "Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2026-09-27",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 5,
      "location_summary": "Northbrook, Illinois • Garner, North Carolina • Shelby, North Carolina + 2 more",
      "locations": [
        {
          "city": "Northbrook",
          "state": "Illinois"
        },
        {
          "city": "Garner",
          "state": "North Carolina"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07578363"
    },
    {
      "nct_id": "NCT01984775",
      "title": "A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "GSK2894512 cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        },
        {
          "name": "Positive control",
          "type": "DRUG"
        },
        {
          "name": "Negative control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2013-10-30",
      "completion_date": "2014-07-02",
      "has_results": false,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984775"
    },
    {
      "nct_id": "NCT02688556",
      "title": "Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "vehicle of OTX-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 745,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-29",
      "last_synced_at": "2026-10-20T06:53:09.867Z",
      "location_count": 3,
      "location_summary": "Rancho Cordova, California • Edgewood, Kentucky • New York, New York",
      "locations": [
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688556"
    }
  ]
}